A large manufacturer client was preparing to launch a biosimilar into a highly competitive and complex market. In this case study, the brand team sought to learn how payers would view the product in relation to key competitors, understand decision drivers and thresholds, and identify potential competitive reactions resulting from any actions taken.
Learn how one pharmaceutical manufacturer overcame inconsistencies in tracking payer coverage and performance across the organization. With the application of a Payer Plan Hierarchy, the client was able to better understand the payer landscape and had a more direct and consistent line of sight on supporting product performance in managed markets contexts.
Section 114 of the Food and Drug Administration Modernization Act of 1997 (FDAMA) was designed to allow pharmaceutical manufacturers to share health economic information with payers. This study shows how, by working in partnership with a pharmaceutical manufacturer, our scientists assessed COPD-related outcomes based on administrative claims data among combination therapy–naive patients—and enabled the client to engage payers on the benefits of its treatment.
A biotech company was preparing to launch a new PET imaging agent for prostate cancer patients with suspected biochemical recurrence into the US market. While a high unmet need continued to exist in recurrent prostate cancer, challenges remained in communicating the value of—and gaining reimbursement for—radiochemical imaging agents. This case study shares the approach to a well-structured preliminary pricing strategy to mitigate these challenges and drive success for the product.
Citing concerns about the methods used to estimate overall survival, a European payer objected to the reimbursement cost-effectiveness analysis submitted by an oncology product manufacturer. Learn how a global systematic literature review and meta-analysis provided a platform for a compelling response.
This case study illustrates a successful program that led to 7 major national health plans offering the manufacturer’s top 2 brands at $0 out-of-pocket to the patient.
In this study, the Precision Health Economics team quantifies how patients value new oncology therapies through research focused on 2 clinical contexts in advanced cancer: metastatic malignant melanoma and metastatic breast cancer.
A pharmaceutical manufacturer was preparing to launch 2 biosimilars with autoimmune disease indications across 6 European markets. With several access challenges for both products anticipated, this case study shares our approach to the assessment of likely access conditions and price potentials at launch, as well as the evidence generation needed to improve those scenarios across markets. The findings were critical to informing the development of a pricing strategy for both biosimilars.
Three HEDIS measures had been issued by the National Committee for Quality Assurance regarding payer performance on smoking cessation among members.
Despite this, payers had a limited understanding of how smoking cessation quality measures were impacting their overall rating vs other regional health or national benchmarks. This study shows how specific smoking cessation support services were promoted to gain improvement in payer coverage for the products while adhering to PhRMA guidelines.
A leading pharmaceutical manufacturer had recently obtained an indication for once daily use (OaD) for erectile dysfunction to supplement its original “as needed (PRN)” indication. With quantity limits (QLs) of 4 to 8 tablets existing on its and similar PRN products, a spillover effect resulted in an accidental blanket QL placed on the drug, even when appropriately prescribed for OaD use. Discover how Precision helped get the QLs reversed.